Literature DB >> 24840329

Heterochromatin protein 1 expression is reduced in human thyroid malignancy.

Maria S Tretiakova1, Sarah D Bond2, David Wheeler2, Alejandro Contreras3, Masha Kocherginsky4, Todd G Kroll5, Tracy K Hale2.   

Abstract

Owing to the loss of heterochromatin integrity that occurs during thyroid tumorigenesis, the expression of Heterochromatin Protein 1 isoforms HP1α and HP1β was assessed by immunohistochemistry in 189 thyroid tumors and non-neoplastic tissues. Expression of HP1β was significantly decreased in all thyroid lesions, except in follicular adenomas, when compared with matched adjacent normal tissue. This loss of HP1β expression may in part be caused by microRNA dysregulation. An example is miR-205, a microRNA that is abundantly upregulated in thyroid carcinomas and shown to reduce the expression of HP1β. In contrast to HP1β, HP1α expression was only reduced in metastatic carcinomas and poorly differentiated lesions. These results suggest the reduction of HP1β followed by a decrease in HP1α contributes to the pathogenesis of thyroid carcinomas, and their loss is a potential marker of thyroid malignancy and metastatic potential, respectively.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24840329     DOI: 10.1038/labinvest.2014.68

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  27 in total

1.  Reduced heterochromatin protein 1-beta (HP1beta) expression is correlated with increased invasive activity in human melanoma cells.

Authors:  Keisuke Nishimura; Yoshifumi S Hirokawa; Hitoshi Mizutani; Taizo Shiraishi
Journal:  Anticancer Res       Date:  2006 Nov-Dec       Impact factor: 2.480

2.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

3.  Genome-wide appraisal of thyroid cancer progression.

Authors:  Volkert B Wreesmann; Ronald A Ghossein; Snehal G Patel; Charles P Harris; Erik A Schnaser; Ashok R Shaha; R Michael Tuttle; Jatin P Shah; Pulivarthi H Rao; Bhuvanesh Singh
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  The WHO histological classification of thyroid tumors: a commentary on the second edition.

Authors:  C Hedinger; E D Williams; L H Sobin
Journal:  Cancer       Date:  1989-03-01       Impact factor: 6.860

5.  Analysis of HP1α regulation in human breast cancer cells.

Authors:  Rune Thomsen; Dennis B Christensen; Sanne Rosborg; Toke E Linnet; Jenny Blechingberg; Anders L Nielsen
Journal:  Mol Carcinog       Date:  2011-03-03       Impact factor: 4.784

6.  Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.

Authors:  Veli-Matti Wasenius; Samuli Hemmer; Eeva Kettunen; Sakari Knuutila; Kaarle Franssila; Heikki Joensuu
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

7.  Heterochromatin protein 1gamma epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers.

Authors:  Masakatsu Takanashi; Kosuke Oikawa; Koji Fujita; Motoshige Kudo; Masao Kinoshita; Masahiko Kuroda
Journal:  Am J Pathol       Date:  2008-12-04       Impact factor: 4.307

8.  The role of YY1 in reduced HP1alpha gene expression in invasive human breast cancer cells.

Authors:  Jason G Lieberthal; Marissa Kaminsky; Christopher N Parkhurst; Naoko Tanese
Journal:  Breast Cancer Res       Date:  2009-06-30       Impact factor: 6.466

Review 9.  Molecular diagnostics and predictors in thyroid cancer.

Authors:  Marina N Nikiforova; Yuri E Nikiforov
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

10.  HP1-beta is required for development of the cerebral neocortex and neuromuscular junctions.

Authors:  Rebecca Aucott; Jörn Bullwinkel; Yang Yu; Wei Shi; Mustafa Billur; Jeremy P Brown; Ursula Menzel; Dimitris Kioussis; Guozheng Wang; Ingrid Reisert; Jörg Weimer; Raj K Pandita; Girdhar G Sharma; Tej K Pandita; Reinald Fundele; Prim B Singh
Journal:  J Cell Biol       Date:  2008-11-17       Impact factor: 10.539

View more
  7 in total

Review 1.  Beyond the histone tale: HP1α deregulation in breast cancer epigenetics.

Authors:  Johan Vad-Nielsen; Anders Lade Nielsen
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  Comprehensive analysis of the prognosis for chromobox family in gastric cancer.

Authors:  Kang Lin; Jinfeng Zhu; Cegui Hu; Fanqin Bu; Chen Luo; Xiaojian Zhu; Zhengming Zhu
Journal:  J Gastrointest Oncol       Date:  2020-10

3.  Depletion of HP1α alters the mechanical properties of MCF7 nuclei.

Authors:  Susav Pradhan; Raoul Solomon; Ankita Gangotra; Gleb E Yakubov; Geoff R Willmott; Catherine P Whitby; Tracy K Hale; Martin A K Williams
Journal:  Biophys J       Date:  2021-06-02       Impact factor: 3.699

4.  Identification of the Roles of Chromobox Family Members in Gastric Cancer: A Study Based on Multiple Datasets.

Authors:  Zhuo-Yuan Chen; Shang-Xing Sun; Si-Xian Zhu; Jie Bu
Journal:  Biomed Res Int       Date:  2020-11-05       Impact factor: 3.411

Review 5.  Heterochromatin Protein 1: A Multiplayer in Cancer Progression.

Authors:  Yu Hyun Jeon; Go Woon Kim; So Yeon Kim; Sang Ah Yi; Jung Yoo; Ji Yoon Kim; Sang Wu Lee; So Hee Kwon
Journal:  Cancers (Basel)       Date:  2022-02-01       Impact factor: 6.639

6.  Expression and Prognostic Value of Chromobox Family Proteins in Esophageal Cancer.

Authors:  Jin Liu; Haixiang Shen; Xiangliu Chen; Yongfeng Ding; Haiyong Wang; Nong Xu; Lisong Teng
Journal:  Genes (Basel)       Date:  2022-09-03       Impact factor: 4.141

7.  CBX1 Indicates Poor Outcomes and Exerts Oncogenic Activity in Hepatocellular Carcinoma.

Authors:  Yu-Feng Yang; Ying-Hua Pan; Qiu-Hong Tian; Dan-Chun Wu; Shu-Guang Su
Journal:  Transl Oncol       Date:  2018-07-19       Impact factor: 4.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.